Adcirca
FDA Approves Breo Ellipta to Treat COPD »
"The U.S. Food and Drug Administration today approved Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary di"...
Adcirca
OVERDOSE
Single doses up to 500 mg have been given to healthy male subjects, and multiple daily doses up to 100 mg have been given to male patients with erectile dysfunction. Adverse reactions were similar to those seen at lower doses. Doses greater than 40 mg have not been studied in patients with pulmonary arterial hypertension. In cases of overdose, standard supportive measures should be adopted as needed. Hemodialysis contributes negligibly to tadalafil elimination.
CONTRAINDICATIONS
Concomitant Organic Nitrates
Do not use ADCIRCA (tadalafil tablets) in patients who are using any form of organic nitrate, either regularly or intermittently. ADCIRCA (tadalafil tablets) potentiates the hypotensive effect of nitrates. This potentiation is thought to result from the combined effects of nitrates and ADCIRCA (tadalafil tablets) on the nitric oxide/cGMP pathway [see CLINICAL PHARMACOLOGY].
Hypersensitivity Reactions
ADCIRCA (tadalafil tablets) is contraindicated in patients with a known serious hypersensitivity to tadalafil (ADCIRCA (tadalafil tablets) or CIALIS). Hypersensitivity reactions have been reported, including Stevens-Johnson syndrome and exfoliative dermatitis [see ADVERSE REACTIONS].
Last reviewed on RxList: 4/4/2011
This monograph has been modified to include the generic and brand name in many instances.
Additional Adcirca Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Women's Health
Find out what women really need.
Updated & New
